Woolcool is setting new standards in cold chain logistics for the distribution of highly temperature sensitive pharmaceuticals, from livestock and human vaccines to insulin to Botox, using sustainable, natural materials to make a positive impact on logistics, businesses, individuals and the environment.*
 
Temperature Sensitive Pharmaceuticals can be rendered ineffective if they are not maintained within their specific temperature range, which is a real challenge for complex supply chains and significant variations in global ambient temperatures. Woolcool, regardless of these fluctuations, will maintain the required temperatures within the insulated packaging, so whatever is going on outside becomes irrelevant.
 
So real is the challenge that in 2013 the European Commission published revised ‘Guidelines on Good Distribution Practice of Medicinal Products for Human Use’ to ensure stricter procedures and greater accountability throughout the supply chain. These new Guidelines not only included tight temperature controls of refrigerated medicines in the Cold Chain (2°C to 8°C) but also Controlled Room Temperature (CRT) products (15°C to 25°C).
 
The UK government backed Technology Strategy Board has recognized the potential of Woolcool as the solution to the supply chain challenge of these temperature sensitive pharmaceuticals and funded further research and development specifically for this purpose.
 
Woolcool has now been independently validated to the 2013 EU GDP standards required for approval by The Medicines and Healthcare Products Regulatory Agency (MHRA) to maintain internal temperatures between 2°C and 8°C for at least 72 hours. Several major players have already switched to Woolcool, including leading distributors of pharmacy, dental and veterinary suppliers as well as certain NHS hospitals.